Cone-Rod Dystrophy at IOC 2027

Cone-rod dystrophy (CRD) refers to a collection of genetic eye conditions that affect the cone and rod photoreceptor cells in the retina, crucial for both daylight and nighttime vision. Unlike other forms of retinal degeneration, CRD initially impacts central and color vision more severely than peripheral vision, as cones deteriorate faster than rods. Symptoms typically include reduced visual acuity, sensitivity to light, color vision deficits, and, in advanced stages, peripheral vision loss.

Genetic mutations are responsible for CRD, with inheritance patterns that can be autosomal recessive, dominant, or X-linked. Diagnosis involves thorough eye examinations, visual field testing, electroretinography (ERG), and genetic testing. While no cure exists, management focuses on symptom relief and adaptive strategies. These include low-vision aids, assistive technologies, and genetic counseling to manage the condition and assess familial risks. Ongoing research aims to develop gene therapies and other treatments to slow disease progression and improve the quality of life for individuals affected by CRD.